Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

ANIX - Anixa Biosciences Inc


IEX Last Trade
3.35
0.030   0.896%

Share volume: 37,010
Last Updated: Fri 30 Aug 2024 09:59:50 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$3.32
0.03
0.90%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
22%
Profitability 25%
Dept financing 5%
Liquidity 50%
Performance 16%
Company vs Stock growth
vs
Performance
5 Days
5.03%
1 Month
8.09%
3 Months
31.50%
6 Months
-4.84%
1 Year
-8.49%
2 Year
-20.10%
Key data
Stock price
$3.35
P/E Ratio 
0.00
DAY RANGE
$3.29 - N/A
EPS 
$0.00
52 WEEK RANGE
$2.15 - $5.13
52 WEEK CHANGE
-$0.08
MARKET CAP 
106.902 M
YIELD 
N/A
SHARES OUTSTANDING 
32.006 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
09/06/2024
BETA 
0.68
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$51,341
AVERAGE 30 VOLUME 
$69,362
Company detail
CEO: Amit Kumar
Region: US
Website: https://www.anixa.com/
Employees: 9
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

itus develops and acquires patented technologies for the purposes of patent monetization and patent assertion. the company currently has 8 patent portfolios in the areas of key based web conferencing encryption, encrypted cellular communications, nano field emission display (“nfed”), micro electro mechanical systems display (“mems”), j-channel window frame construction, vpn multicast communications, internet telephonic gateway, and enhanced auction technologies. itus’s management team has over 30 years of combined experience in patent monetization and patent assertion, and has generated in excess of $150 million patent licensing revenues

Recent news